Myriad Genetics (NASDAQ:MYGN) just reported results for the first quarter of 2024.
- Myriad Genetics reported earnings per share of -1 cent. This was above the analyst estimate for EPS of -10 cents.
- The company reported revenue of $202.20 million.
- This was 4.63% better than the analyst estimate for revenue of $193.26 million.